Guidelines for Management of Cancer-Associated Thrombosis

Tags: thromboembolism, cancer

As of June 2018, current guidelines from the American College of Chest Physicians (ACCP) and the National Comprehensive Cancer Network (NCCN) recommend LMWH for the first 3-6 months of treatment for cancer-associated thrombosis, and long-term anticoagulation for as long as malignancy is present. Ongoing clinical trials comparing LMWH to DOAC therapy for initial treatment of cancer-associated thrombosis may alter these guidelines in the future.

**OBTAIN BASELINE LABS**

- PT/aPTT
- HCT
- Platelets (and q2-5 days during the first 2 weeks of LMWH therapy)
- Serum creatinine

**OBTAIN PATIENT'S TOTAL BODY WEIGHT (TBW) IN KG**

**CALCULATE CREATININE CLEARANCE**

- Male: \([(140\text{ - age}) \times \text{TBW}] / 72 \times \text{Scr}\)
- Female: CrCl (male) x 0.85

**INITIAL THERAPY (FIRST MONTH)**

<table>
<thead>
<tr>
<th>TBW (kg)</th>
<th>OUTPATIENT THERAPY</th>
<th>INPATIENT THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 45 kg</td>
<td>Enoxaparin 1mg/kg SQ q12h [or dalteparin 200 U/kg SQ q24h (rounded to nearest 500 units using 10,000 U/ml graduated syringe)]</td>
<td>Enoxaparin 1mg/kg SQ q12h</td>
</tr>
<tr>
<td>46-56</td>
<td>Enoxaparin 1mg/kg SQ q12h [or dalteparin 10,000 units syringe SQ q24h]</td>
<td></td>
</tr>
<tr>
<td>57-68</td>
<td>Enoxaparin 1mg/kg SQ q12h [or dalteparin 12,500 units syringe SQ q24h]</td>
<td></td>
</tr>
<tr>
<td>69-82</td>
<td>Enoxaparin 1mg/kg SQ q12h [or dalteparin 15,000 units syringe SQ q24h]</td>
<td></td>
</tr>
<tr>
<td>83-98</td>
<td>Enoxaparin 1mg/kg SQ q12h [or dalteparin 18,000 units syringe SQ q24h]</td>
<td></td>
</tr>
<tr>
<td>&gt;99 kg</td>
<td>Enoxaparin 1mg/kg SQ q12h</td>
<td></td>
</tr>
</tbody>
</table>

CrCl 30-60 ml: Enoxaparin 0.85mg/kg SQ q12h
<table>
<thead>
<tr>
<th>CrCl &lt; 30 ml/min</th>
<th>Enoxaparin 1mg/kg SQ q24h</th>
<th>IV heparin</th>
</tr>
</thead>
</table>

## SUBSEQUENT THERAPY (MONTH 2 THROUGH MONTH 3-6)

<table>
<thead>
<tr>
<th>TBW (kg)</th>
<th>OUTPATIENT THERAPY</th>
<th>INPATIENT THERAPY</th>
</tr>
</thead>
</table>
| < 45 kg  | Enoxaparin 1.5mg/kg SQ q24h  
(or dalteparin 150 U/kg SQ q24h  
(rounded to nearest 500 units using 10,000 U/ml graduated syringe)) | Enoxaparin 1.5mg/kg SQ q24h |
| 46-56    | Enoxaparin 1.5mg/kg SQ q24h  
OR  
(or dalteparin 7500 units SQ q24h) | Enoxaparin 1.5mg/kg SQ q24h |
| 57-68    | Enoxaparin 1.5mg/kg SQ q24h  
OR  
(or dalteparin 10,000 units SQ q24h) | Enoxaparin 1.5mg/kg SQ q24h |
| 69-82    | Enoxaparin 1.5mg/kg SQ q24h  
OR  
(or dalteparin 12,500 units SQ q24h) | Enoxaparin 1.5mg/kg SQ q24h |
| 83-98    | Enoxaparin 1.5mg/kg SQ q24h  
OR  
(or dalteparin 15,000 units SQ q24h) | Enoxaparin 1.5mg/kg SQ q24h |
| >99 kg   | Enoxaparin 1mg/kg SQ q12h  
| Enoxaparin 1mg/kg SQ q12h |
| CrCl 30-60 ml/min | Enoxaparin 0.85mg/kg SQ q12h or 1.5mg/kg SQ q24h  
| Enoxaparin 0.85mg/kg SQ q12h or 1.5mg/kg SQ q24h |
| CrCl <30 ml/min | Enoxaparin 1mg/kg SQ q24h  
| IV heparin |

## CHRONIC THERAPY (AFTER THE FIRST 3-6 MONTHS)

- Transition to warfarin (goal INR of 2-3)
- OR continue LMWH based on pt preference
- OR consider DOAC therapy as long as patient is not receiving potentially interacting concurrent therapies

## REFERENCES

• NCCN guidelines: http://www.nccn.org/professionals/physician_gls/default.asp

Source URL (modified on 04/25/2018 - 14:50): http://depts.washington.edu/anticoag/home/content/guidelines-management-cancer-associated-thrombosis-0